Cellular stress and coagulation factor production: when more is not necessarily better
Journal of Thrombosis and Haemostasis · 2023-12 · 21 (12) · 3329-3341
DOI: 10.1016/j.jtha.2023.10.005 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Thrombosis and Haemostasis, 2023-12. Verfasst von Zhouji Chen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Degenerative Diseases Program, Center for Genetic Diseases and Aging Research, SBP Medical Discovery Institute, California, USA. Hauptthemen laut MEDLINE: Hemophilia A, Hemophilia B. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NHLBI, F. Hoffmann-La Roche.
Abstract (Originalsprache)
Remarkably, it has been 40 years since the isolation of the 2 genes involved in hemophilia A (HA) and hemophilia B (HB), encoding clotting factor (F) VIII (FVIII) and FIX, respectively. Over the years, these advances led to the development of purified recombinant protein factors that are free of contaminating viruses from human pooled plasma for hemophilia treatments, reducing the morbidity and mortality previously associated with human plasma-derived clotting factors. These discoveries also paved the way for modified factors that have increased plasma half-lives. Importantly, more recent advances have led to the development and Food and Drug Administration approval of a hepatocyte-targeted, adeno-associated viral vector-mediated gene transfer approach for HA and HB. However, major concerns regarding the durability and safety of HA gene therapy remain to be resolved. Compared with FIX, FVIII is a much larger protein that is prone to misfolding and aggregation in the endoplasmic reticulum and is poorly secreted by the mammalian cells. Due to the constraint of the packaging capacity of adeno-associated viral vector, B-domain deleted FVIII rather than the full-length protein is used for HA gene therapy. Like full-length FVIII, B-domain deleted FVIII misfolds and is inefficiently secreted. Its expression in hepatocytes activates the cellular unfolded protein response, which is deleterious for hepatocyte function and survival and has the potential to drive hepatocellular carcinoma. This review is focused on our current understanding of factors limiting FVIII secretion and the potential pathophysiological consequences upon expression in hepatocytes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Degenerative Diseases Program, Center for Genetic Diseases and Aging Research, SBP Medical Discovery Institute, California, USA.
- Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University, Indianapolis, Indiana, USA.
- Degenerative Diseases Program, Center for Genetic Diseases and Aging Research, SBP Medical Discovery Institute, California, USA. Electronic address: rkaufman@sbpdiscovery.org.
Förderung
- NHLBI NIH HHS
- NHLBI
- F. Hoffmann-La Roche
Zitieren
APA
Chen, Z., Herzog, R. W., & Kaufman, R. J. (2023). Cellular stress and coagulation factor production: when more is not necessarily better. Journal of Thrombosis and Haemostasis, 21(12), 3329-3341. https://doi.org/10.1016/j.jtha.2023.10.005
Vancouver
Chen Z, Herzog RW, Kaufman RJ. Cellular stress and coagulation factor production: when more is not necessarily better. Journal of Thrombosis and Haemostasis. 2023;21(12):3329-3341. doi:10.1016/j.jtha.2023.10.005
BibTeX
@article{Chen2023,
author = {Chen, Zhouji and Herzog, Roland W and Kaufman, Randal J},
title = {Cellular stress and coagulation factor production: when more is not necessarily better},
journal = {Journal of Thrombosis and Haemostasis},
year = {2023},
volume = {21},
number = {12},
pages = {3329--3341},
doi = {10.1016/j.jtha.2023.10.005}
}
EUVIMED